title: Insights on GRACE (Gender, Race, And Clinical Experience) from the patient's perspective: GRACE participant survey.
abstract: The Gender, Race And Clinical Experience (GRACE) study was conducted between October 2006 and December 2008 to evaluate sex- and race-based differences in outcomes after treatment with a darunavir/ritonavir-based antiretroviral regimen. Between June 2010 and June 2011, former participants of the GRACE trial at participating sites were asked to complete a 40-item questionnaire as part of the GRACE Participant Survey study, with a primary objective of assessing patients' characteristics, experiences, and opinions about participation in GRACE. Of 243 potential survey respondents, 151 (62%) completed the survey. Respondents were representative of the overall GRACE population and were predominantly female (64%); fewer were black, and more reported recreational drug use compared with nonrespondents (55% vs. 62% and 17% vs. 10%, respectively). Access to treatment (41%) and too many blood draws (26%) were reported as the best and worst part of GRACE, respectively. Support from study site staff was reported as the most important factor in completing the study (47%). Factors associated with nonadherence, study discontinuation, and poor virologic response in univariate analyses were being the primary caregiver for children, unemployment, and transportation difficulties, respectively. Patients with these characteristics may be at risk of poor study outcomes and may benefit from additional adherence and retention strategies in future studies and routine clinical care.
authors.affiliation: Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA 19107, USA. Kathleen.squires@jefferson.edu
authors.forename: Kathleen
authors.initials: K
authors.lastname: Squires
authors.forename: Judith
authors.initials: J
authors.lastname: Feinberg
authors.forename: Dawn Averitt
authors.initials: DA
authors.lastname: Bridge
authors.forename: Judith
authors.initials: J
authors.lastname: Currier
authors.forename: Robert
authors.initials: R
authors.lastname: Ryan
authors.forename: Setareh
authors.initials: S
authors.lastname: Seyedkazemi
authors.forename: Yaswant K
authors.initials: YK
authors.lastname: Dayaram
authors.forename: Joseph
authors.initials: J
authors.lastname: Mrus
mesh_terms: D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003430:Cross-Sectional Studies; D000069454:Darunavir; D005260:Female; D005783:Gender Identity; D015658:HIV Infections / Q000188:drug therapy* / Q000208:ethnology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D019538:Health Care Surveys; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011647:Puerto Rico; D044469:Racial Groups / Q000706:statistics & numerical data; D019438:Ritonavir / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014481:United States; D019562:Viral Load; D016903:Drug Monitoring
chemical_list: D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D019438:Ritonavir; D000069454:Darunavir